Degenerative Cervical Myelopathy
BMJ 360:k186, Davies, B.M.,et al, 2018
Hereditary Spastic Paraplegia:From Diagnosis to Emerging Therapeutic Approaches
Lancet Neurol 18:1136-1146, Shribman,S.,et al, 2019
Pantothenate Kinase - Associated Neurodegeneration (PKAN)
Emedicine.Medscape Sept, Hanna, P.A. & Benbadis, S.R., 2018
DARS-Associated Leukoencephalopathy can Mimic a Steroid-Responsive Neuroinflammatory Disorder
Neurol 84:226-230,218, Wolf, N.I.,et al, 2015
Summary of Evidence-Based Guideline: Complementary and Alternative Medicine in Multiple Sclerosis
Neurol 82:1083-1092, Yadav, V.,et al, 2014
Cerebral Palsy
Lancet 383:1240-1248, Colver, A.,et al, 2014
Systematic Review: Efficacy and Safety of Medical Marijuana in Selected Neurologic Disorders
Neurol 82:1556-1563, Koppel, B.S.,et al, 2014
The Management of Spasticity in Adults
BMJ 349:g4737, Nair, K.P.S. & Marsden, J., 2014
Clinicopath Conf, Infantile Krabbe Disease
NEJM 362:346-356, Case 3-2010, 2010
Practice Parameter: Pharmacologic Treatment of Spasticity in Children and Adolescents with Cerebral Palsy (an Evidence-Based Review): Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society
Neurol 74:336-343, Delgado,M.R.,et al, 2010
Cerebral Palsy
Lancet 363:1619-1631, Koman,L.A.,et al, 2004
Stiff-Person Syndrome
The Neurologist 10:131-137, Murinson,B.B., 2004
Oral Antispastic Drugs in Nonprogressive Neurologic Diseases
Neurol 63:1357-1363, Montane,E.,et al, 2004
Intrathecal Baclofen Withdrawal Mimicking Sepsis
J Emerg Med 24:423-427, Kao,L.W.,e tal, 2003
Friedreich Ataxia
Arch Neurol 59:743-747, Lynch,D.R.,et al, 2002
Safety, Tolerability, and Efficacy of Orally Administered Cannabinoids in MS
Neurol 58:1404-1407,1323, Killestein,J.,et al, 2002
Open-Label Dose-Titration Safety and Efficacy Study of Tizanidine Hydrocholoride in the Treatment of Spasticity Associated With Chronic Stroke
Stroke 32:1841-1846, Gelber,D.A.,et al, 2001
Uses of Botulinum Toxin Injection in Medicine Today
BMJ 320:161-165, Munchau,A. & Bhatia,K.P., 2000
Multiple Sclerosis, Side Effects of Interferon Beta Therapy and Their Management
Neurol 53:1622-1627, Walther,E.U.&Hohlfeld,R., 1999
A 29-Year-Old Man with Multiple Sclerosis
JAMA 280:1432-1439, Rudick,R.A., 1998
Tizanidine for Spasticity
The Medical Letter 39:62, , 1997
Chronic Spinal Cord Injury
NEJM 330:550-556, Ditunno,J.F.&Formal,C.S., 1994
Motor Neuron Disease
JNNP 57:886-896, Leigh,P.N.&Ray-Chaudhuri,K., 1994
Botulinum Toxin in the Cerebral Palsies
BMJ 309:1526-1527, Neville,B., 1994
Tizanidine Treatment of Spasticity Caused by Multiple Sclerosis:Results of a Double-Blinded, Placebo-Controlled Trial
Neurol 44:S34-S43, Smith,C.,et al, 1994
A Double-Blind, Placebo-Controlled Trial of Tizanidine in the Treatment of Spasticity Caused by Multiple Sclerosis
Neurol 44:S70-S78, Barnes,M.P.,et al, 1994
Efficacy and Safety of Tizanidine in the Treatment of Spasticity in Patients with Spinal Cord Injury
Neurol 44:S44-S52, Nance,P.W.,et al, 1994
Continuous Intrathecal Baclofen Infusion for Spasticity of Cerebral Origin
JAMA 270:2475-2477, Albright,A.L.,et al, 1993
Myelopathic Neurosarcoidosis:Diagnostic Value of Enhanced MRI
Neurol 41:150-151, Sauter,M.K.,et al, 1991
Intrathecal Baclofen for Spasticity in Cerebral Palsy
JAMA 265:1418-1422, Albright,A.L.,et al, 1991
Neurologic Aspects of Cobalamin Deficiency
Medicine 70:229-245, Healton,E.B.,et al, 1991
Reversal of a Neurologic Paraneoplastic Syndrome with Octreotide (Sandostatin) in a Pt with Glucagonoma
Am J Med 91:434-436, Holmes,A.,et al, 1991
Treatment of Spasticity with Botulinum Toxin:A Double-Blind Study
Ann Neurol 28:512-515, Snow,B.J.,et al, 1990
Intrathecal Baclofen for Severe Spinal Spasticity
NEJM 320:1517-1521, 1553-15551989., Penn,R.D.,et al, 1989
Spasticity
et al (Part 1 & 2) NEJM 304:28-33, 96-99., Young,R.R., 1981